The therapeutic potential of 5-HT1A receptors: a patent review
暂无分享,去创建一个
E. Lacivita | M. Leopoldo | F. Berardi | R. Perrone | Pantaleo Di Pilato | P. De Giorgio | N. Colabufo | Paola De Giorgio
[1] M. De Vivo,et al. Characterization of the 5-hydroxytryptamine1a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. , 1986, The Journal of pharmacology and experimental therapeutics.
[2] G. Aghajanian,et al. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists , 1987, Synapse.
[3] C. de Montigny,et al. Modification of 5‐HT neuron properties by sustained administration of the 5‐HT1A agonist gepirone: Electrophysiological studies in the rat brain , 1987, Synapse.
[4] G. Aghajanian,et al. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons , 1988, Neuropharmacology.
[5] D. Middlemiss,et al. Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. , 1988, Journal of medicinal chemistry.
[6] J. Bockaert,et al. Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. , 1988, Molecular pharmacology.
[7] M. Jann,et al. Buspirone: An Update on a Unique Anxiolytic Agent , 1988, Pharmacotherapy.
[8] S. Haj-Dahmane,et al. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. , 1990, The Journal of pharmacology and experimental therapeutics.
[9] A. Akaike,et al. Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997 , 1990, Neuropharmacology.
[10] L. Acsády,et al. Serotonergic control of the hippocampus via local inhibitory interneurons. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[11] R. Fuller. Role of serotonin in therapy of depression and related disorders. , 1991, The Journal of clinical psychiatry.
[12] S. Watson,et al. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic study , 1991, Brain Research.
[13] P. Hooff,et al. Actions of 5‐hydroxytryptamine and 5‐HT1A receptor ligands on rat dorso‐lateral septal neurones in vitro , 1992, British journal of pharmacology.
[14] T. Freund,et al. GABAergic Interneurons are the Major Postsynaptic Targets of Median Raphe Afferents in the Rat Dentate Gyrus , 1992, The European journal of neuroscience.
[15] M. Sketch,et al. Effect of buspirone on withdrawal symptoms associated with smoking cessation. , 1992, Archives of internal medicine.
[16] T. Bliss,et al. A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.
[17] J. Raymond,et al. Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. , 1993, Biochemistry.
[18] Iain P. Chessell,et al. Neurotransmission—the link integrating Alzheimer research? , 1994, Trends in Neurosciences.
[19] J. Cassel,et al. Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications , 1995, Neuroscience.
[20] Mustapha Riad,et al. Immunocytochemical localization of serotonin1A receptors in the rat central nervous system , 1996, The Journal of comparative neurology.
[21] D. Bakish,et al. Serotonin in the Central Nervous System and Periphery. , 1997 .
[22] M. Abate,et al. Buspirone Use for Smoking Cessation , 1998, The Annals of pharmacotherapy.
[23] T. Kojima,et al. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. , 1999, The Journal of pharmacology and experimental therapeutics.
[24] J. Raymond,et al. The recombinant 5‐HT1A receptor: G protein coupling and signalling pathways , 1999, British journal of pharmacology.
[25] R. Ridley,et al. The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys , 2000, Neuropharmacology.
[26] L. Levine,et al. The 5-HT1A Receptor: an unkept promise? , 2000 .
[27] L. Descarries,et al. Somatodendritic localization of 5‐HT1A and preterminal axonal localization of 5‐HT1B serotonin receptors in adult rat brain , 2000, The Journal of comparative neurology.
[28] trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines. , 2001, Journal of medicinal chemistry.
[29] Daniel Hoyer,et al. Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.
[30] M. López-Rodríguez,et al. Arylpiperazine derivatives acting at 5-HT(1A) receptors. , 2002, Current medicinal chemistry.
[31] S. L. Nicholson,et al. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. , 2002, European journal of neurology.
[32] Judith S. Rose,et al. Effects of buspirone in withdrawal from opiates. , 2003, The American journal on addictions.
[33] P. Blier,et al. Is there a role for 5-HT1A agonists in the treatment of depression? , 2003, Biological Psychiatry.
[34] Yasuhiro Kaneda,et al. Serotonin receptors : their key role in drugs to treat schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[35] R. Galani,et al. Intraseptal injection of the 5-HT1A/5-HT7 agonist 8-OH-DPAT and working memory in rats , 2004, Psychopharmacology.
[36] Xiaojie Shi,et al. Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. , 2004, Journal of medicinal chemistry.
[37] C. J. Maclean,et al. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset , 2005, Psychopharmacology.
[38] I. Lucki,et al. Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test , 2005, Psychopharmacology.
[39] J. Barrett,et al. Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.
[40] F. Colpaert. 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. , 2006, Current opinion in investigational drugs.
[41] O. Stiedl,et al. 5-Hydroxytryptamine 1A Receptor Blockade Facilitates Aversive Learning in Mice: Interactions with Cholinergic and Glutamatergic Mechanisms , 2006, Journal of Pharmacology and Experimental Therapeutics.
[42] J. Castaǹer,et al. Sarizotan hydrochloride : Antidyskinetic drug 5-HT1A receptor agonist dopamine D2 receptor ligand , 2006 .
[43] O. Rascol,et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.
[44] Ji Woong Kim. Role of 5-HT1A Receptors in Learning and Memory , 2007 .
[45] P. Svenningsson,et al. The role of 5-HT1A receptors in learning and memory , 2008, Behavioural Brain Research.
[46] Charles A. Marsden,et al. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory , 2008 .
[47] E. Lacivita,et al. 5-HT1A receptor, an old target for new therapeutic agents. , 2008, Current topics in medicinal chemistry.
[48] G. Mengod,et al. Distribution and neurochemical characterization of neurons expressing GIRK channels in the rat brain , 2008, The Journal of comparative neurology.
[49] Rony Seger,et al. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. , 2010, Methods in molecular biology.
[50] O. Rascol,et al. Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[51] K. Fabel,et al. Oppositional Effects of Serotonin Receptors 5-HT1a, 2, and 2c in the Regulation of Adult Hippocampal Neurogenesis , 2009, Front. Mol. Neurosci..
[52] R. Depoortère,et al. F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. , 2010, The international journal of neuropsychopharmacology.
[53] S. Shimizu,et al. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[54] L. Goff,et al. Region- and phase-dependent effects of 5-HT1A and 5-HT2C receptor activation on adult neurogenesis , 2010, European Neuropsychopharmacology.
[55] Abigail M Polter,et al. 5-HT1A receptor-regulated signal transduction pathways in brain. , 2010, Cellular signalling.
[56] O. Rascol,et al. Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials , 2011, Movement disorders : official journal of the Movement Disorder Society.
[57] N. Meanwell. Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.
[58] A. Newman-Tancredi,et al. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties , 2011, Psychopharmacology.
[59] Thomas Ruhland,et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. , 2011, Journal of medicinal chemistry.
[60] G. Ming,et al. Modification of hippocampal circuitry by adult neurogenesis , 2012, Developmental neurobiology.
[61] L. Citrome. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? , 2014, International journal of clinical practice.